Actinogen Medical Ltd (ACW) - Total Liabilities
Based on the latest financial reports, Actinogen Medical Ltd (ACW) has total liabilities worth AU$6.15 Million AUD (≈ $4.35 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Actinogen Medical Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
Actinogen Medical Ltd - Total Liabilities Trend (2006–2025)
This chart illustrates how Actinogen Medical Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Actinogen Medical Ltd balance sheet assets.
Actinogen Medical Ltd Competitors by Total Liabilities
The table below lists competitors of Actinogen Medical Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SKM Egg Products Export (India) Limited
NSE:SKMEGGPROD
|
India | Rs2.43 Billion |
|
Alicon Castalloy Limited
NSE:ALICON
|
India | Rs7.09 Billion |
|
Biosyent Inc.
V:RX
|
Canada | CA$7.88 Million |
|
Gurit Holding AG
SW:GURN
|
Switzerland | CHF182.25 Million |
|
Bank Mnc Internasional Tbk
JK:BABP
|
Indonesia | Rp17.35 Trillion |
|
Action Electronics Co Ltd
TW:3024
|
Taiwan | NT$1.50 Billion |
|
Harbour Link Group Bhd
KLSE:2062
|
Malaysia | RM324.48 Million |
|
Waldencast Acquisition Corp
NASDAQ:WALD
|
USA | $316.10 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Actinogen Medical Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ACW net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Actinogen Medical Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Actinogen Medical Ltd (2006–2025)
The table below shows the annual total liabilities of Actinogen Medical Ltd from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$6.15 Million ≈ $4.35 Million |
+280.42% |
| 2024-06-30 | AU$1.62 Million ≈ $1.14 Million |
-10.34% |
| 2023-06-30 | AU$1.80 Million ≈ $1.27 Million |
+15.01% |
| 2022-06-30 | AU$1.57 Million ≈ $1.11 Million |
+70.21% |
| 2021-06-30 | AU$920.32K ≈ $651.19K |
-12.16% |
| 2020-06-30 | AU$1.05 Million ≈ $741.29K |
+87.96% |
| 2019-06-30 | AU$557.39K ≈ $394.39K |
-27.45% |
| 2018-06-30 | AU$768.25K ≈ $543.59K |
-9.00% |
| 2017-06-30 | AU$844.26K ≈ $597.37K |
+2.43% |
| 2016-06-30 | AU$824.20K ≈ $583.18K |
+270.20% |
| 2015-06-30 | AU$222.64K ≈ $157.53K |
+345.93% |
| 2014-06-30 | AU$49.93K ≈ $35.33K |
-38.60% |
| 2013-06-30 | AU$81.32K ≈ $57.54K |
-31.55% |
| 2012-06-30 | AU$118.81K ≈ $84.06K |
+25.48% |
| 2011-06-30 | AU$94.68K ≈ $66.99K |
-45.45% |
| 2010-06-30 | AU$173.58K ≈ $122.82K |
+64.66% |
| 2009-06-30 | AU$105.42K ≈ $74.59K |
+28.04% |
| 2008-06-30 | AU$82.33K ≈ $58.26K |
+37.22% |
| 2007-06-30 | AU$60.00K ≈ $42.45K |
+106.90% |
| 2006-06-30 | AU$29.00K ≈ $20.52K |
-- |
About Actinogen Medical Ltd
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other ne… Read more